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Abstract
Broncho-alveolar lavage is an important diagnostic in-
strument in lung transplantation. It can give insight into
the mechanisms of  acute and chronic rejection, but can
also be of interest to explore the possible effects of
new therapies. This has particularly been the case with
azithromycin as add-on therapy for chronic rejection.
Lung transplantation (LTx) is a well-
-established treatment modality for patients
with end-stage pulmonary disease1. A major
complication in transplant patients is acute
rejection (AR). Approximately 50-70% of
LTx patients experience at least one episode
of  AR, which occurs most frequently dur-
ing the first 3 months after LTx2. The diag-
nosis of AR is based on clinical findings and/
or histologic confirmation by means of
transbronchial biopsy, the latter being char-
acterized by an intra-graft perivascular and/
or peribronchial infiltration of  inflammato-
ry cells. It has been shown that the frequen-
cy and the severity of  AR episodes are asso-
ciated with an increased risk of  chronic
rejection or Bronchiolitis Obliterans Syn-
drome (BOS), which is the main obstacle for
long-term success of  LTx3.
In addition to transbronchial biopsies and
lung function tests, analysis of  broncho-
-alveolar lavage (BAL) provides us with an-
other means of  assessing inflammatory
changes in LTx. It is well known that lym-
Furthermore BAL after lung transplantation is impor-
tant to differentiate between infection and rejection
and the changes in the cellular profile may be of  prog-
nostic significance.
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phocytes are increased in BAL of  patients
with AR4, however, with a lot of  variation in
cell profiles at different time points after
LTx5. It is currently believed that AR is or-
chestrated by the helper (CD4+) subset of
T-lymphocytes, which are activated by do-
nor allopeptides. The cytokines produced by
these activated T-cells, in turn stimulate the
proliferation, chemotaxis and/or activation
of  cytotoxic (CD8+) T-lymphocytes, neu-
trophils and alveolar macrophages. These
inflammatory cells contribute to graft inju-
ry6. IL-17 is a specific T-lymphocyte derived
cytokine capable of inducing neutrophilic
migration and activation both in vitro and in
vivo7, via the production of  IL-8, the major
neutrophilic chemoattractant cytokine. Both
IL-8 and neutrophils have been identified as
important triggers in the onset and progres-
sion of BOS8.
We have particularly been interested in BAL
during acute and chronic rejection. As has
already been demonstrated by several au-
thors, we confirmed an increased amount of
lymphocytes in the BAL fluid during acute
rejection, but, for the first time we draw at-
tention to the BAL neutrophilia, which was
also significantly increased (Fig. 1) and cor-
Fig. 1 – BAL cellular profile during acute rejection (from ref 9)
The cellular profile of the bronchoalveolar lavage (BAL) samples in the control (•; n = 17) and acute rejection (AR; n = 9) groups. a)
Total counts of inflammatory cells in the BAL fluid (BALF) at day 28. b) Percentage of inflammatory cells in the BALF at day 28. c)
Lymphocyte numbers of both the control and AR groups at days 28 and 90. d) Neutrophil numbers of both the control and AR groups
at days 28 and 90. Neut.: neutrophil; Lymph.: lymphocytes; Macro.: macrophages; Eosino.: eosinophils. *: p<0.05; **: p<0.01.
The role of  BAL in lung transplantation
G M Verleden
R E V I S T A  P O R T U G U E S A  D E  P N E U M O L O G I A
Vol XIII   Suplemento 2   Outubro 2007
S 61
related, as well as the lymphocytes, with the
degree of  acute rejection. Together with an
increase in lymphocytes and neutrophils,
there was a significant increase in IL-17,
which has previously been shown to be in-
volved in acute rejection in renal and cardiac
transplantation9 (Fig. 2). IL-17 has been dem-
onstrated to be able to induce IL-8 produc-
tion from human airways smooth muscle
cells in vitro10 and is indeed recognized as a
major chemo-attractant of  neutrophils, pos-
sibly by the induction of  IL-8 from airways
smooth muscle and also from epithelial cells,
suggesting a continuum between acute and
chronic rejection.
During chronic rejection, BAL is mostly char-
acterized by an increased neutrophilia and
an increase in IL-8, with a correlation being
present between these two parameters. Treat-
ment of  BOS is very disappointing, howev-
er, recently, interest has been growing in the
role of  azithromycin as additional treat-
ment11,12, since it is believed that neo-macro-
lides possess anti-inflammatory effects spe-
cifically directed to neutrophils and IL-8. We
could indeed demonstrate that 3 months of
treatment with azithromycin may significant-
ly increase the pulmonary function parame-
ters in patients with BOS, however, only in
these patients presenting with an initially high
BAL neutrophilia, whereas in the other pa-
tients (with a BAL neutrophilia <10%), there
was no improvement at all in the FEV1.
Moreover, the initial BAL neutrophilia cor-
related with the changes in FEV1 after 3
months of  treatment (Fig. 3)13. These data
Fig. 2 – Correlation between IL-17 in BAL and the degree
of acute rejection (from ref 9)
Interleukin (IL)-17 mRNA and protein levels measured in
bronchoalveolar lavage (BAL) 28 days after lung
transplantation using qPCR and ELISA. The mRNA levels
are expressed as a ratio of IL-17 over β-actin and the
protein levels are expressed pg·mL–1. Correlation between
a) IL-17 mRNA and the grade of acute rejection (AR; r =
0.53, p = 0.0056, n = 26) and b) IL-17 protein and the gra-
de of AR (r = 0.42, p = 0.0032, n = 26).
Fig. 3 – Correlation between initial BAL neutrophilia and
changes in FEV1 after 3 months of treatment with
azithromycin (from ref 13)
Spearman rank correlation (with 95% confidence intervals
calculated by univariate regression model) between initial
BAL neutrophilia (in %) and changes in FEV1 (in % from
baseline) after 3 months of treatment with azithromycin in
the whole group (r=0.74, p=0.0026).
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suggest that patients with BOS and a high
BAL neutrophilia may represent an inflam-
matory phase of  BOS and are amenable to
additional treatment, whereas the non-
-neutrophilic BAL patients may represent
true chronic rejection, manifested by oblit-
erative bronchiolitis, which has a bad prog-
nosis and is almost impossible to treat.
In conclusion: BAL in lung transplantation
offers a very important instrument to fur-
ther unravel the pathophysiology of  acute
and chronic rejection, to investigate the pos-
sible mechanisms of  action of  new treat-
ments and maybe also to predict the further
prognosis of the patient, although this needs
further confirmation14.
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